| abstract |
The present invention relates to a bosentan controlled release oral formulation and a bosentan controlled release oral formulation comprising bosentan, an active ingredient which is a pharmaceutically acceptable salt thereof, or a solvate thereof, and a hydrophilic polymer as a sustained release base. A method for producing a preparation and a method for treating pulmonary arterial hypertension are provided. According to the present invention, the number of doses of bosentan, a pharmaceutically acceptable salt thereof, or a solvate thereof can be reduced, and the convenience of taking can be improved, whereby the compliance with medication can be improved. There are advantages. Furthermore, there is an advantage that occurrence of side effects can be reduced as well as an increase in therapeutic effect. Also, the present invention has an advantage that a bosentan controlled release oral preparation can be effectively produced. |